new tirzepatide drug FDA approves weight loss with remarkable track record Newer Weight-Loss Drugs Not Cost-effective

While Medicare Part D also excludes weight loss drugs, TFL and Medicare have separate rules and appeals processes

Meta-analysis was conducted using Comprehensive Meta-Analysis (version 3.0, Biostat, Englewood, NJ, USA, 2022)

doi: 10.1016/j.anaerobe.2019.102135 [DOI] [PubMed] [Google Scholar] 37

Insurance Coverage Limitations While these medications are proven effective for their intended uses, insurance coverage can be limited for off-label uses

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest Statements Conflict of interest Within the last 36 months, FK has served on scientific advisory panels and/or been part of speaker's bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gubra, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Sanofi and Zealand Pharma

Persists after cycling off tirzepatide and requires active management to prevent rebound